One week away! Register for our free CE webinar on canine aging.
This content isn’t available here
Access this content and more in the LinkedIn app
Loyal
Biotechnology Research
San Francisco, CA 8,048 followers
Loyal is developing the first-ever drugs intended to extend the healthspan and lifespan of dogs.
About us
Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the lifespan and healthspan of dogs. In other words, our mission is to help dogs live longer, healthier lives. We’ve already achieved significant milestones on our path to gaining FDA approval for the first lifespan extension drug for any species. We have three products in our pipeline and expect to bring the first product to market in 2025. Our team includes scientists, veterinarians, engineers, operators, and creatives. Join us in our mission to help dogs everywhere.
- Website
-
http://loyal.com
External link for Loyal
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
San Francisco, CA 94103, US
Employees at Loyal
Updates
-
In celebration of November Senior Pet Month, we’re partnering with the Senior and Geriatric Dog Society to host our first live CE webinar on aging in dogs. → Dr. Brennen McKenzie will kick-off the webinar by connecting geroscience and geriatrics, introducing the principles and underlying biology of canine aging, and describing the key clinical impacts of this process. → Senior and Geriatric Dog Society co-founders Lisa Lippman, D.V.M. and Monica Tarantino will discuss strategies for how to assess and manage geriatric canine patients. They’ll also teach you how to set up a consistent, systematic senior care program for dogs in your practice. → All participants will get 1 hour of CE credits. Did we mention it’s free to attend? Hope to see you there! Register → https://lnkd.in/g__FCi-X
-
-
Hook 'em Horns! Thanks, @TexasExes for highlighting our founder and CEO and what she's accomplishing to bring dogs longer, healthier lives.
This week on Hello Longhorn, we're introducing Celine Halioua, BSA '17, the founder and CEO of Loyal. As a 2024 Outstanding Young Texas Ex, she is developing drugs to healthily extend dogs' lifespans. Hello Longhorn is a Texas Exes podcast introducing you to Longhorn entrepreneurs and business leaders. Listen to Hello Longhorn every Monday wherever you get your podcasts → https://lnkd.in/gacytwZ8
-
"It's been a wild ride." Thanks Immad Akhund and Rajat Suri for having our CEO and Founder Celine Halioua on your podcast to share about our mission, vision, and the risks involved to get dog longevity drugs to market.
Most investors have clear mental models for evaluating startups—especially in tech, where traction and product-market fit are key indicators. But what happens when you're building something entirely new? On this episode of Founders in Arms, Rajat Suri and I sat down with Celine Halioua, founder and CEO of Loyal, who is developing the first FDA-approved longevity drugs for dogs. Celine shared how she evolved her pitch from "people love dogs" to one that broke down market potential, success milestones, and the economics of drug development—and how that change helped her raise $140M from non-biotech investors. We also talked about FDA regulation, alternative funding paths, and the complexities of going public early—even when public markets might value you higher. This is a good one for founders building in emerging markets. Check out the full conversation in the links below.
-
Product people look here ⬇️⬇️⬇️ (I'm currently on parental leave, but I really think our engineering team is awesome and would be happy to talk with you about Loyal or connect you with someone!)
We're hiring a Sr. Product Manager to lead our e-commerce product buildout yeah, you read that right. loyal's building TECHNOLOGY PRODUCTS! be a core part of launching the first dog longevity drug (hopefully!!!!) https://lnkd.in/gUQa_xKp
-
“Anything we can do to possibly help to extend the lives of other dogs, that’s where we want to be,” said Kenny, whose dog Bella is enrolled in the STAY study, the clinical trial for LOY-002, our senior dog program. That’s exactly where we want to be too! https://lnkd.in/gN74tMNE Thank you Dr. Douglas Stramel, Alex Boyér and KDFW-TV FOX 4 Dallas-Fort Worth for sharing this story. If you think your dog may be eligible for the STAY study, fill out our survey: https://lnkd.in/gty6nAwY
Clinical trial underway in North Texas for new drug that could extend a dog's lifespan
fox4news.com
-
Want free vet check-ups for four years while contributing to science? Join our groundbreaking clinical trial for LOY-002, our drug intended to extend dogs’ healthy lifespan. We’re still recruiting participants at 70 clinical partner sites across the U.S. Learn about benefits, qualifications, and why dog owners and vets joined the STAY study, and see if your senior dog is eligible → https://lnkd.in/gty6nAwY
-
Hard to believe it's been four years, Loyal!! What a ride!
-
-
How’s the STAY study going? Hear from Dr. Ellen Ratcliff, our VP of Clinical and Veterinary Medicine. The STAY study is our pivotal effectiveness study for LOY-002. This drug aims to make senior dogs live longer by targeting the metabolic dysfunction that occurs in dogs as they age. It mimics caloric restriction, which is one of the only proven mechanisms in the scientific literature to increase lifespan in dogs. Get the low-down on what makes the STAY study different from most clinical studies and how it’s making a splash in the veterinary industry -> https://lnkd.in/eHCQX2Sc
-
Check out this dvm360® video interview with Dr. Brennen McKenzie, as he discusses how metabolic dysfunction impairs health in older dogs. https://lnkd.in/gdZBt7rN
Understanding how metabolic dysfunction affects canine aging
dvm360.com